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ABSTRACT
Wayne Luther Glore. Targeting Galectin-1 as a Potential Therapeutic
for Glioblastoma (Under guidance from Arabinda Das & Michael
Ostrowski)
Glioblastoma (GB) is classified by the World Health Organization
(WHO) as a Grade IV astrocytoma characterized by a poor prognosis
with a median survival time ranging from 15-16 months. The
standard of care for GB is surgery followed by radiation and
chemotherapy treatment with Temozolomide, but even with the
aggressive treatment, GB recurrence occurs in approximately 90 %
of the patient population. New treatment options have been FDA
approved which include Novocure’s Optune Device and Genentech’s
Avastin, but neither of these options drastically change survival time
or quality of life. Galectin-1 (Gal-1), a protein with a high affinity to
bind β-galactosides, has been implicated in other cancers such as
renal cancer, liver cancer, and urothelial cancer and plays a role
ranging from angiogenesis to altering the tumor microenvironment
for immune suppression. Little research has been conducted
investigating Gal-1’s role in GB so the aim of our in vitro and in vivo
studies was to gain a better understanding of Gal-1’s potential
mechanisms in GB and see the feasibility of Gal-1 inhibition as a
potential treatment option. The data collected illustrated roles of Gal1 in angiogenesis, in apoptosis, and in facilitation of a hypoxic
environment. Inhibition of Gal-1 shows signs of being a plausible
treatment option especially if given coadjuvant to an Anti-VEGF
therapy.
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Chapter 1
Introduction
Glioblastoma (GB) is categorized by the World Health
Organization (WHO) as a grade IV astrocytic tumor and stems
from astrocytes, a star shape glia cell that protects the brain
from infections and diseases. The exact cause for the onset of
the brain tumor is unknown but begins when astrocytes start to
rapidly proliferate to form tumors due to variations in genetic
expression that promote cell growth. GB can cause a multitude
of symptoms that include invasion and decay of healthy brain
tissue surrounding the tumor, pressure from fluids building up,
and a disruption of cerebrospinal fluid circulation through the
brain. The tumor is typically found in the cerebral hemispheres
of the brain, but it has the capacity to occur at any location in
the brain. It is a cancer that is plagued with low survival rates
with the median survival rate at 12-18 months. The disease’s 5year survival rate is approximately 10%. There are many
barriers that prevent development of effective treatment for GB.
Barriers to Treatment
Multiple barriers thwart effective treatment of GB. First, GB
has high heterogeneity regarding the genetic composition of the
tumor. GB cells capitulate multiple neurodevelopmental and

1

lineage differentiation processes to become their specified
neuronal cells in the brain.1 This differentiation of cells leads to
the genetic diversity that encompasses GB. Second, genetic
expression profile differs between patients with GB. No one or
two genes are the primary genetic drivers for tumor growth and
eventual GB. A list of several indicated genes for GB
progression and sustained growth include TP 53, PTEN, EGFR,
IDH 1, IDH 2, MAP 3K1, NF 1, TET 1, and FGFR4. Due to the
multitude of different genes expressed and their mutations in
GB, it is difficult to target a single gene that will have beneficial
treatment for a vast subset of patients. Even if one specific gene
became readily targetable the treatment would still face
difficulty in delivery to the tumor because of the blood brain
barrier (BBB).
Advances in GB treatment prove futile due to the BBB, a
defense system that limits the entry of molecules and blocks the
entrance of toxins or infectious molecules into the brain. The
BBB is the barrier between the cerebral capillary blood and the
interstitial fluid of the brain consisting of capillary endothelial
cells, basement membrane, neuroglial membrane, and glial
podocytes, i.e., projections of astrocytes.2 Tight junctions are
formed between the endothelial cells preventing entry from
blood borne pathogens and other potential deleterious products.
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Only certain products can bypass the blood brain barrier these
include lipid soluble molecules, and receptor-mediated transport
of glucose and ions to pass through. Drugs given by intravenous
(IV) injection and subcutaneous injection have low probability of
crossing the BBB and being delivered to the target site of the
tumor. The inability to easily cross the BBB with innovative
treatment ideas is a powerful barrier to new treatment methods
being developed and eventually FDA approved.
Recurrent Glioblastoma Progression
Recurrent GB occurs in majority of patients with initial GB.
The difficulty resides in removing the whole tumor and infiltrating
tissue around the tumor and complete resection is uncommon.
No established standard of care has been established for
recurrent GB and treatment generally consist of another round
of tumor re-section followed by radiation and treatment with
Temozolomide. Survival time is relatively low and still rest at a
little over a year. Recurrent GB is less responsive to treatment
and has a high rate of drug and radiation resistance.
Current Standard of Care
The standard of care for initial GB is maximal surgical
resection followed by radiotherapy then Temozolomide (TMZ). A
new treatment Bevacizumab (Avastin) was investigated
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specifically for recurrent GB, but overall survival (OS) was not
increased only quality of life (QOL). The benefits of TMZ +
Bevacizumab help with increased time of progression free
survival. The current standard of care was established in 2005
with maximal safe resection and then concomitant daily
temozolomide and radiotherapy followed by adjuvant
temozolomide showed improvement in median OS and 2-year
survival.3 TMZ is a chemotherapy treatment that is an alkylating
agent that binds to DNA in cancer cells preventing their division
and growth. Clinicians and advancing research identified the
importance of DNA repair protein O6-methylguanine-DNA
methyltransferase (MGMT) in understanding the likeliness of
tumor response to TMZ treatment. MGMT would repair the
damaged DNA caused by TMZ but in cases where the MGMT is
methylated it loses function and eventually degrades. Lack of
methylation of the MGMT gene is associated with a stronger
likeliness of TMZ resistance by the tumor in patients who have
GB. 4-7
Avastin: Potential Implications GB and Recurrent GB
Treatment
Bevacizumab, also known as Avastin, is a drug which is made by
the company Genentech. Bevacizumab is a humanized monoclonal
Anti- Vascular Endothelial Growth Factor (VEGF) antibody that
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blocks all three isoforms of VEGF-A and blocks interactions with
the VEGF R2 receptor. VEGF expression in GB and recurrent GB
is associated with vascular permeability, tumor cell proliferation,
and tumor cell migration.

Schematic 1.1: Blockage of VEGF Signaling Cascades by
Avastin (Made through Biorender)
Schematic 1.1 illustrates the pathways that become active, both
PI3K/AKT and RAF/MEK/ERK1/2, to promote vascular
development for the tumor and increase proliferation of tumor cells.
Ligand VEGF-A, the ligand that typically binds to the VEGF R2
receptor, has other roles involved in activating migration and
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proliferation of endothelial cells (ECs) to maximize angiogenic
capacity of the tumor microenvironment. Abundance of VEGF-A
growth factor creates a gradient of soluble chemo attractants for
endothelial cells to migrate towards.8 VEGF inhibition has the
potential to be moderately dangerous to certain patient subsets,
and recent evidence demonstrates that Anti-VEGF mAb inhibition
leads to problems such as nephrotoxicity and can be deadly to
patients.9 VEGF is an essential growth factor to promote
angiogenesis and healthy functioning of blood vessels. Thus, there
is a necessity to look at other forms or methods to target cancer’s
highly immunosuppressive immune environment.
Chapter 2: Review of the Literature
This chapter will discuss the current literature in the field of
Glioblastoma and general cancer research by examining
mechanisms of Recurrent Glioblastoma, current trend in cancer
therapeutics, Galectin-1 in cancer progression and
immunosuppression, the role of both hypoxia and radiation in the
TME and describe why our therapeutic approach is innovative.
Mechanisms of Recurrent Glioblastoma
Many different cellular and extracellular mechanisms play a part
in establishing resistance to treatment for recurrent GB. Cancer
stem cells (CSCs) in the tumor have properties that lead to
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adaptation and response to the microenvironment and treatment
methods. CSCs are referred to as tumor initiating cells due to their
high capacity to generate tumors in xenograft models.10-11 CSCs for
GB are derived from neural stem cells and are believed to be the
driving factors that lead to the genetic diversity encompassing the
tumor. Cancer researchers have a consensus that cancer stem
cells are what drives resistance and recurrence. The common
marker for CSCs is CD 133.12 Recurrent Glioblastoma is
challenging to make effective therapeutics for due to its strong
drug-resistance through hypoxia and vast expression of CSCs,
immunosuppression, and similarities to tissue necrosis due to
irradiation.
Recurrent GB cells gain a further capability for drug suppression.
Initial GB naturally has small amplitude of drug suppression
capacity due to inefficiency of drug deliver. The previously
discussed blood brain barrier limits the quantity of treatment that
gets to the targeted tumor in the brain. There is no efficient way of
direct targeting removal of the entire tumor due to the stress that
additional surgery will have on the brain and the potential disruption
of the glymphatic system. Recent evidence illustrates that there is a
small set of cancer cells within the tumor that are named persisters
due to their relative similarity to colonies in E.coli culture that are
persistent to antibiotic treatment.13 These cancer persister cells
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gain drug-tolerant capabilities through mechanisms of either
chromatin or metabolic remodeling.13 Evidence has shown that
treatment resistance for GB can derive from gene mutations and
slow growing cancer persister cells after long term treatment with
TMZ.14 The metabolic, cell survival, and epigenetic changes that
occur in cancer persisters are in response to slow cell growth
characterized by the environment.15 Along with cancer persisters,
cells have proteins that are transporters that pump the attempted
treatments out of the tumor.
ATP binding cassette (ABC) transporters are efflux transporters
that pump out different chemotherapeutics. Analysis of their
expression can help guide the understanding of multiple drug
resistance (MDR) in multiple cancers and patients . ABCB 1, a
specific ABC transporter protein, has many different drugs that act
as a substrate but the major one is TMZ.16 Expression of this
protein indicates that the GB will be less responsive to the standard
of care and have a high potential to reoccur. These ABC
transporters and their expression may be increased in recurrent GB
and that is why they are less likely to have a response to treatment.
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Schematic 1.2: Major Players of Immunosuppression in
Glioblastoma (Made through Biorender)
The tumor microenvironment in GB and recurrent GB is highly
immunosuppressive and suppresses anti-tumor activity led by
immune effector cells. There is an increase in regulatory T
lymphocytes (Tregs) in the tumor microenvironment (TME) and
peripheral blood. Immunosuppression is mediated by heightened
amounts of Tregs expressing FoxP3 in the peripheral blood which
inhibits immune responses and antitumor activity.17-23 The increase
in circulating Tregs reduces the amount of cytotoxic CD 4+ and
CD8+ T cells that are viable to attack the tumor.
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Experimental Therapeutics
The CDC stated statistics that illustrate that Cancer is still the
second highest cause of death in the United States. Treatment is
still ineffective and new methods are being created, brought into
clinical trials, and advancing to the clinical setting. The push
towards advancing therapy lies in methods of CAR-T therapy, and
specifically targeted antibodies. CAR-T therapy has had proven
success with blood cancers but has not been looked at extensively
at other cancers. It would not work in the brain due to unknown risk
with interactions of neurons and how it could modulate cognitive
and motor function. The other form of advancement comes in
target-specific antibodies. These antibodies look at targeting a
specific protein or activating an immune response to attack the
tumor.
Table 1:1- Approved Antibodies for Treatment of Cancer (Cancer
Research Institute)
Drug
Alemtuzumab
Bevacizumab
Cetuximab
Daratumumab
Rituximab
Tafasitamab
Trastuzumab

Trademark Name Target
Campath
CD 52
Avastin
VEGF
Erbitux
EGFR
Darzalex
CD 38
Rituxan
CD 20
Monjuvi
CD 19
Herceptin
HER 2

Disease
Leukemia
Brain, cervical, colorectal, kidney, liver, lung, and ovarian cancer
Colorectal cancer and head & neck cancer
Multiple myeloma, colorectal, esophageal, liver, lung, & stomach cancer
Leukemia and Lymphoma
Lymphoma
Breast, espohageal, and stomach cancer

Table 1:1 illustrates the current approved monoclonal antibodies
that target specific pathways that are promoted in cancer to
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increase cell proliferation and cell migration. As shown by the chart
the only one approved for glioblastoma, the brain cancer, is
Avastin. This chart demonstrates that there is a need to develop
more therapeutic options for glioblastoma. Further looking into
other pathways and mechanism of targets to block could improve
the efficacy of treatment and provide patients with more options
tailored to their medical needs.
Galectin-1’s Role in Cancer and Immunosuppression
Galectin-1 (Gal-1) is a lectin which is a carbohydrate binding
protein that has a high affinity for binding β- galactosides. The
composition of the protein includes two subunits of a total size
of14.5 kDa (135 aa) that reside in a dynamic dimerization
equilibrium.24 Gal-1’s structure is influenced by 2 anti-parallel βsheets with a conserved topology of a carbohydrate recognition
domain.25 Gal-1’s CRD contains a high affinity to bind LacNAcbearing structures via van der Waals interactions and hydrogen
bond formation.25 The binding is mediated by key amino acids that
include His45, Asn47, Arg49, Val60, Asn62, Trp69, Glu72, and
Arg74.25 Gal-1 is considerably upregulated and overexpressed in
inflammatory macrophages, immunosuppressive DCs26-28, activated
T and B cells29-30, CD4+CD 25+ Tregs and uterine NK cells31-32.
Gal-1 regulates the immune effector cell populations previously
stated by interactions with properly glycosylated cell receptors that
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include CD 45, CD 43, CD 3, CD 2, CD 4, CD 7, CD 69, and pre-B
cell receptor (pre-BCR).33-40 Through cellular interactions stated in
paragraphs below, Gal-1 has emerged as a novel regulatory
checkpoint that positively influences immune evasive programs of
cancer cells’ by inducing T-cell exhaustion, limiting survival of Tcells, favor an expansion of regulatory T-cells, de-activate natural
killer (NK) cells, and polarize myeloid cells towards an
immunosuppressive phenotype.24 Gal-1 has many implications in
adaptive and innate immunity. Attached to the cell membrane Gal-1
selectively promotes apoptosis of Th 1 and Th 17 cells41, induces Il10 secretion42-45, inhibits T-cell trafficking46and decreases nitric
oxide (NO) production by macrophages.47-48
Gal-1 alters T-cells viability by creating disruptions that promote
apoptotic factors and limit efficiency of TCR signal transduction.
The Gal-1 receptors CD 3, CD 4, CD 2, CD 45, GM1, and CD 43
impact TCR signal transduction through reorganization at opposite
poles during synaptogenesis and distal pole complex formation. 3740,49-51

The lectin’s immunoregulatory capabilities may result from its

capacity to modulate TCR signal transduction, T-cell synaptic
organization, and T-cell polarity. Gal-1 also acts as a TCR
antagonist and limits sustained TCR signaling during continued CD
8+ T-cell activation.52 Gal-1 acts as an autocrine negative
regulatory of CD 8+ burst size and provides concrete identification
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of modulation of the TCR ligand binding in time of T-cell
activation.52 Gal-1 regulates CD 8+ and CD 4+ T cell populations
while increasing the percentage of regulatory T-cells (Tregs). The
protein engages with the receptor CD 45 and instructs the T-cell to
a regulatory T-cell signature which is characterized by high Il 10
and Il 21 expression.53 Gal-1 modifies the c-Maf/aryl hydrocarbon
receptor pathway in these instances. 53 Gal-1 alters T-cell fate and
promotes apoptotic factors for eventual T-cell death. Gal-1
mediated cell death transpires independent of caspase activation
by nuclear translocation of mitochondrial endonuclease G which is
not accompanied by cytochrome C- release.54 Gal-1 mediates t-cell
viability by selectively deleting through apoptotic or TCR disruption
in CD8+ and CD 4+ cells while simultaneously increasing the
populations of TREGS. Gal-1 induces apoptosis in CD 8+ and CD
4+ t cells through disruption of TCR signal transduction, while
increasing TREGS which induce expression of Il-10 and Il-21
expression activating a M2 phenotype in macrophages and
promoting an anti-inflammatory response in the immune effector
cell populations. These mechanisms lead to a heightened
immunosuppressive environment for the cancer to thrive in and
grow undetected.
Cancers promote a tumor microenvironment that is highly
hypoxic and lacks adequate oxygen supply. Recent findings
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suggest hypoxia increases the amounts of b1-6GlcNAc-branched
N-glycans and poly-LacNAc structures, reduces a2-6 sialylation,
and induces slight changes in asialo-core-1 O-glycans in
comparison to normal healthy oxygen conditions55 Refractory
tumors occur even in the presence of treatment with Anti-VEGF
mAb and in these instances Gal-1 expression increased. The
recent findings showed that Gal-1 maintained activation of VEGF
activated angiogenesis and proliferation pathways through overexpression phospho Akt (Thr308), Akt (Ser473), and Erk1/2.55
Overexpression of Gal-1 reduces sensitivity to Anti-Vegf treatment
by keeping the PI3K-AKT-MTOR and Ras-Raf-MEK-ERK pathways
open. Gal-1 keeps these pathways open by interactions with
VEGFR2 through N-glycosylation-dependent mechanisms.55 These
studies show that not only is Gal-1 promoting an anti-inflammatory
response in the tumor microenvironment, but Gal-1 is also keeping
angiogenesis and proliferation pathways active through complex Nglycan interactions with cell surface receptors like VEGF-A.
Schematic 1.3. is below to help illustrate the binding of VEGF by
Gal-1 through complex β 1,6 N glycan branching.
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Schematic 1.3. Galectin-1 Complex N Glycan Branching to VEGF
(Made through Biorender)
Role of Hypoxia in the Tumor Microenvironment
Hypoxia plays a critical role in helping to establish tumor
angiogenesis and helping to create a tumor microenvironment that
favors the metabolic switch of cancer cells from oxidative
phosphorylation to anerobic glycolysis. Hypoxia inducible factor 1
(HIF-1) is made up of two subunits, HIF-1α and HIF-1β. HIF-1α is
oxygen dependent and in normal conditions hif-1 α is degraded by
the proteosome by being marked with a hydroxyl group (OH) for
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degradation by proline-hydroxylase-2 (PHD-2) and by vonHippelLindau (VHL)-ubiquitin ligase complexes.56-57 As tumor cells
proliferate limiting the quantity of oxygen in the microenvironment,
hif-1 α stabilizes and is no longer marked and degraded. Hif-1 α
stabilization leads to binding of Hif-1α to Hif-1β generating the Hif-1
complex. The Hif-1 complex binds to the binding site which consist
of the core sequence 5’-CGTG-3’ of the hypoxic response element
(HRE) domain that sits on regulatory regions of target genes to
activate expression. Over 70 known genes that play roles that
include angiogenesis, cell proliferation, apoptosis, and cell
stemness are transcriptionally regulated by Hif-1 complex.58
Activation of the complex leads to an increase in VEGF expression
supporting angiogenesis and the reduction of oxygen in the
environment making treatments such as chemotherapy and
radiation less successful at attacking GB.
Role of Radiation in Cancer
Radiation is a treatment technique that has been used since the
advancement of science and computer technology. Through
molecular biology techniques radiation has been shown to cause
single and double strand breaks in DNA which can leads to signals
of apoptosis and cell senescence. Radiation decreases oxygen in
the microenvironment leading to an increase in HIF-1 activity and
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high doses can increase the glycan environment surrounding the
tumor.
Chapter 3
Introduction
Gaining knowledge from studying human tumor samples,
specifically GB, is essential to further understanding of the
environment and protein expression through the tumor. Our lab has
access to human samples that we can analyze, and it gives us a
capacity to analyze if certain treatment methods are worth
pursuing. Previous research indicates Gal-1 plays a role in helping
establish an immunosuppressive tumor environment and leads to
progression of cancer. The purpose of these experiments, Gal-1
expression profiling and tumor staining, was to gain a better grasp
on the tumor microenvironment and characterize Galectin-1
expression in patient samples. High Gal-1 would validate the
notions that this protein plays some sort of role in GB and that it is
worth being investigated as a potential therapeutic target.
Materials and Methods
Human samples were supplied through a Neurosurgeon that is in
our department (Department of Neurosurgery). The samples were
placed on ice and were immediately placed in -80°C freezer until
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further use. All collection methods followed approved IRB protocols.
Western Blot
Tissue was cut into smaller pieces with scalpel and suspended in
500 µl of Homogenizing Buffer (2 mM EDTA, 50 mM Tris-Cl (pH
7.5), 0.5 mM DTT)(dithiothreitol)). Tissue was sonicated and 5µl
was pipetted and placed in a glass vial filled with 1ml of DI water.
After that step, the glass vial was filled with 1ml of Coomassie
assay buffer and vortexed. 200µl was placed in a 96-well plate
reader along with standards of 0, 2, 5, 10, 20, and 40 µg of BSA
(concentration 1µg/µl) and the plate was read at 495 nm. Protein
content was calculated, and tissue was diluted to 1µg/1ml with 500
µl of Sample Buffer and Homogenizing Buffer + Sample Buffer + 1
% HB+SB Bromophenol. The tubes were stored in -80°C freezer
until was ready to use.
Tubes were taken out of freezer and placed in warm water. The
tubes were then vortexed. Bio-rad Pre-cast TGX 4-15%
Tris/Glycine Page Buffer 15 well (15µl) were placed in a
electrophoresis chamber filled with SDS running buffer. Each well
was filled with 7.5 µl of specific human sample protein, and the
system ran at 125 volts for 1.5 hours. Once the protein ran to the
end of the gel, it was placed on a PVDF membrane sandwiched
between to filter papers between sponges that were soaked in
Transfer buffer. The PVDF membrane in the Transfer buffer was
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ran at 12 volts for two hours. After this the membrane was removed
and placed in a blocking solution of 2% non-fat milk in TBST. The
membrane was blocked for 1 hour, then the blocking buffer was
discarded and replaced with primary antibody at a concentration of
(1:2,000) in 2%non-fat milk TBST. The membrane was incubated
overnight at 4°C. After incubation, the primary antibody solution
was discarded and saved for further Western Blots. The membrane
was washed three times with TBST for 12 minutes each. TBST was
discarded and the membrane was placed in the secondary antibody
(1:5000) 2 % non- fat milk TBST solution. The secondary antibody
used is dependent upon the primary antibody. The secondary
antibody was discarded after an hour of incubation at room
temperature. The membrane was washed in TBST and then taken
to a Chemi Doc imager. ECL was prepared by adding equal
solutions of solution A and solution B to a 15 ml tube wrapped in
tinfoil to cover it from light. 1 ml of ECL was placed on each
membrane once placed an imager. Image was saved to flash-drive
for data- analysis.
Cryostat Sectioning
Tumor samples were sliced into small pieces using a scalpel and
one small piece was taken and placed in tissue freezing medium
(TFM) and allowed to freeze in the medium in the -80° freezer.
Once ready the frozen TFM and tissue were mounted on a cryostat
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specimen chuck. The tissue was sliced at an approximate width of
12 µm and tissues were placed on Fisher Brand Super frost Plus
pre cleaned slides. Slides were correctly labeled and stored in 80°C freezer until ready to go through immunofluorescence
staining.
Immunofluorescence Staining
Slides are taken out of the -80° C freeze and allowed to come to
room temperature by incubating for 45 minutes to an hour. Then
slides are immersed in 95% EtOH for 10 min followed by two
washes in PBS (1X) for 2.5 minutes each. The slides are moved to
a solution of 4% paraformaldehyde dissolved in PBS (1X) where
they are immersed for 15 minutes followed by three washes with
PBS (1X) for 2.5 minutes each. Following the washes with PBS
(1X) the slides are immersed in 0.2% Triton X-100 dissolved in PBS
(1X) for 5 minutes followed by another three washes of PBS (1X)
for 2.5 minutes each. 100µl/slide of 4% serum in PBS(1X) is
applied to each slide for an hour for blocking. The serum is
dependent upon the species of the secondary antibody. In our
experiments the secondary antibody is goat, so the serum is 4%
goat serum in PBS (1X). The 4% goat serum in PBS (1x) is wiped
away from the edges not touching the tissue by a Kimwipe, then
100µl of the primary antibody(1:500 dilution) is applied to each slide
for 2 hours at RT followed by three washes of PBS (1X) at 2.5
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minutes each. After the three washes with PBS (1X), 100µl per
slide of secondary antibody (1: 500 dilution) in 4% goat serum in
PBS (1X) is applied to the slides for 1 hour at RT. Application of the
secondary antibody and the following steps must occur in the dark.
Ensuing secondary antibody incubation, the slides are washed
three times with PBS (1X) at 2.5 minutes each. Kim wipes are used
to dry the edges around the tissue in the slides and a plastic
Pasteur pipette is used to incorporate 1-2 droplets of Vectashield+
Dapi onto the slides. Cover slips follow this process and are placed
over the mounted stained tissue. Slides can be kept for 2-3 days
and are imaged using an Olympus.
Statistical Analysis
For IHC staining 12 images were taken with each of the constraints
that were ROS 1 positive and ROS 1 negative. Western Blots
conducted included 10 samples for each of the patients and 10
samples for the normal brain tissue which was taken from healthy
individuals with no current state of mental disease or disorder. Data
illustrated in this thesis for human patient samples illustrates the
expression conserved through multiple exposure of analysis from
the samples where n is greater than or equal to 10.
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Results

Image 3.1: Staining and Expression Analysis of GB Patient
The sample size for the staining and western blots was 20 patients
and the normal tissue analysis was 12 patients. There were 12
images taken from each patient for the IHC of Ki-67, GFAP, and
Dapi.
Discussion
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The results indicate that Gal-1 is overexpressed in GB patients.
This overexpression leads us to conclude that Gal-1 must play a
role in establishing the tumor and the tumor’s microenvironment to
prevent effective treatment. Immunofluorescence staining of the
tissue indicates that the GB tumors have an extremely high rate of
proliferation (Ki-67), and expression of Glial fibrillary acidic protein
(GFAP). GFAP is a commonly used marker to get an understanding
of the severity of the tumor. The analysis of human samples drives
our lab to look further into Gal-1 expression by conducting various
in vitro and in vivo assays. Our next steps will be to understand
Gal-1 expression in endothelial cells and test its feasibility as a
therapeutic through in vitro drug assay methods.
Chapter 4
Introduction
From analysis of Glioblastoma patients there was an increase in
Gal-1 expression compared to healthy tissues. These results
indicated that this protein has some sort of role in supporting tumor
growth. The goal of these experiments was to validate Gal-1
inhibition as a potential treatment in an in-vitro model while
comparing it to VEGF inhibition and in conjunction with VEGF
inhibition. The second goal of the experiments was to design a co
culture system with GB cells and HUVEC cells. Previous literature
suggest that Gal-1 has strong roles in the extracellular matrix
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(ECM) and endothelial cells. Gal-1 may act similarly to VEGF in
increasing endothelial cell proliferation leading to increased
angiogenesis that supports tumor function and growth. These
experiments aim to answer these questions and provide more
background into relationships Gal-1 has with different factors of
Glioblastoma.
Materials & Methods
In-vitro Drug Treatment of GB Cells
The Glioblastoma cell lines, 43 RG 32 28 24 which were given to us
by the Cleveland Clinic, were either not treated or treated with
Bevacizumab, OTX 008, or Bevacizumab + OTX 008. Cells were
grown until approximately 70% confluency in the flask until
treatment started. The combinational treatment of Bevacizumab +
OTX 008 started with treatment of Bevacizumab on the first day
followed by OTX 008 on the 2nd day. On the 5th day cells were
scraped from the flask and inserted into a 15ml conical tube with 10
ml of media. The cells were spun at 5,000 rpm for 5 minutes, and
the media was discarded, and the cells were frozen in -80°C
freezer until a Bradford assay was ready to be conducted for
protein estimation.
MTT Assay
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A MTT solution was created at a concentration of 5mg/ml dissolved
in PBS. Preparation of MTT solvent was created with 4 mM HCl,
0.1% NP40 in isopropanol. Cells were scrapped from 75cm3 and
spun at 4,000 g for 5 min. Then supernatant was poured off and the
cells were suspended in 100 µl of serum free media. After
suspension 50 µl of cells + serum free media were pipetted into the
96 plate well. 50 µl of MTT was placed in each well. The 96 well
plate was incubated for 3 hours at 37 ºC. Add 150 µL of MTT
solvent into each well. Wrap plate in foil and shake on an orbital
shaker for 15 minutes. Read absorbance at OD=590 nm.
Western Blots
Cells were lysed and protease inhibitors were utilized. Cells were
suspended in 100 µl of Homogenizing Buffer (2 mM EDTA, 50 mM
Tris-Cl (pH 7.5), 0.5 mM DTT)(dithiothreitol)) After suspension cells
were transferred to tubes with correct labeling. The suspended cells
were sonicated. Glass tubes were filled with 1 ml of deionized (DI)
water, 5 µL of suspended protein+ HB, 1ml of Coomassie assay
buffer, and then vortexed. 200 µl of solution from the glass tube
was taken and plated on a 96 well plate. The standards for the
Bradford Assay were 0,2,5,10,20,40 (µg/µl) BSA duplicated and
plated. Two solutions of 200µl were taken from each glass tube and
then averaged and calculated to make 1µg/ 200µl solutions with
HB+SB (Bromo-phenol) added for purpose of western blots. Gels
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were loaded and run at an hour and half at 100 volts. The gels were
then sandwiched between a PVDF membrane and two membrane
filters and placed in transfer buffer and run at 12 volts for two hours.
Then membranes were placed in blocking buffer (2% non-fat milk in
TBST) for one hour. Then the selected primary antibody was
diluted 1:2,000 in 2% non- fat milk TBST. The blocking buffer was
discarded and the membranes were placed in the primary antibody
cocktail overnight at 0 to -4°C on a shaker. The next day the
membranes are allowed to come near room temperature then are
discarded and washed three times for 12 minutes with TBST. After
that the membranes are placed in a secondary antibody cocktail
that includes the selected secondary antibody at a concentration
ranging from 1:5,000-1:8,000 in 2% nonfat milk and TBST. The
membranes are incubated at room temperature for an hour. The
membranes are washed another 3 times with TBST and then are
ready to be imaged by a Bio-Rad ChemiDoc imager. Membranes
are pulled from their containers one by one and drained of TBST
and placed on the screen of the imager. ECL is prepared ahead of
time with equal parts of solution A and solution B. 1.5 of ECL
reagent is pipetted on the membrane, and then the membrane is
imaged for protein expression of selected primary antibody.
Caspase 3 Assay
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Cells that were undergoing treatment were lysed and protein
estimation calculations (Bradford Assay) were conducted.
Approximately 250µg of protein of each sample were taken for use
in the caspase 3 colorimetric assay (Sigma Aldrich). The microliter
quantity that gave 250µg of protein was taken for each sample and
placed in the specific well. The cell treatments calculated came
from triplicate of the treatments conducted. After the cell lysate was
placed in the specific wells, 980µl of 1x Assay Buffer was added to
each well. The Assay Buffer was formed by diluting 10x assay
buffer to the correct volume with the 17 megaohm water provided in
the kit. 10µL of Caspase 3 substrate was then added to well. The
caspase 3 substrate was dissolved in DMSO and diluted in 1x
assay buffer to bring the Caspase 3 substrate from 20mM down to
2 mM. The plate was then covered and incubated at 37°C
overnight. The next day the absorption of the plate was run at 405
nm.
Co-Culture Proliferation Assay with Bevacizumab
Co-culture assays helped to establish the role of Galectin-1 as a
factor similar to VEGF in its promotion of angiogenesis. For the coculture the bottom layer of cells on the system were Human
umbilical vein endothelial cells (HUVEC) and the system was set up
once the HUVEC reached approximately 20,000 cells. The number
of cells was validated through cell counting on a hemocytometer.
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The cells were counted 3 times at each day indicated with the
experiment run in triplicate. P values did not exceed .05. The
glioblastoma cell line was plated on a 0.4µm filter system position
above the endothelial cells. Schematic 3.1 shows the set up of the
co culture system. Once the Glioblastoma cells were plated on the
porous filter membrane and were treated either with either no
treatment, dose of Bevacizumab, or dose of Bevacizumab and
OTX008. Following this treatment of the Glioblastoma cells, the
quantity of HUVEC is counted at the intervals of initial (0 days), 3
days, 7 days, and 10 days. Counting was done through trypan blue
dying for cell viability and counted with the utilization of the square
system of the hemocytometer. The three constraints of treatment
methods went as follows: untreated, Bevacizumab, and
Bevacizumab+ OTX008. There were 4 co culture systems of each
treatment method to be able to effectively count cells at 0, 3, 7, and
10 day periods. After treatment was finished. Cells were blocked
with protease inhibitors and lysed to run Westerns to look at
Galectin-1 expression.
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Schematic 4.1: Treatment of Bevacizumab in Glioblastoma Cells
Co Cultured with Endothelial Cells
Co-Culture Proliferation Assay with Radiation
A co-culture assay was set up in a similar style to that of the
previously describe co-culture with Bevacizumab treatment, but this
time focusing on radiation. Scientific literature shows mixed reviews
on the influence of radiation in cancer. Previous research indicates
that radiation, more specifically higher doses of radiation lead to
healthy cells and tissue surrounding the tumor turning into necrosis
which allows for tumor growth and helps in making a larger barrier
to thwart treatment options. This study was done to further develop
and comprehend the relationship between radiation and Gal-1
expression. Glioblastoma cells were grown and plated on a 0.4µm
porous membrane that was placed in a proximity dependent
manner above the endothelial cells. The endothelial cells were
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plated before the Glioblastoma cells on the bottom of the petri dish
at a population of approximately 20,000 cells. 6 gy of radiation was

given consecutively (3 times total) after 72 hours of the co culture
being in place. The treatment constraints were untreated, radiation,
radiation and OTX008 together. Endothelial cells were stained with
trypan blue to validate cell viability and counted utilizing a
hemocytometer. Endothelial cells had protease inhibitors added
and cells were lysed through sonication for purpose of protein
estimation and Western Blot analysis.
Schematic 4.2: Treatment of Glioblastoma Cells with Radiation Co
cultured with Endothelial Cells
Cell Counting with Hemocytometer
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The goal of the co-culture assays is to analyze different treatment
options and their influence on angiogenesis by looking at
endothelial cell proliferation. Endothelial cells must be counted to
effectively analyze their characteristics in the presence of
treatment. The device used is called a hemocytometer and has little
grid like squares that can be utilized for a full estimation of the cell
count for different subsets. The cells were counted 3 times each
where n=3. By having 9 counts of cells it gives a better estimation
of cell count through the triplicate of experiments conducted.
Statistical Analysis
All studies conducted are at constraints where n is greater than or
equal to three. For cell proliferation assays, cell counts were
conducted three times for each time point and the Glioblastoma cell
co culture with endothelial cells was at n is greater than or equal to
three. Each of the figures indicates the values calculated between
time points and multiple stages of data collection. The percentage
of standard of error for cell counting did not exceed .05 for any of
the constraints.
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Results

Image 4.1 Gal-1 Expression in Bevacizumab Treated Co-Culture

Image 4.2 Bevacizumab and OTX 008 HUVEC Proliferation
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Image 4.3 Galectin-1 Expression Radiation Treated Co-culture
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Image 4.4 Radiation and OTX 008 HUVEC Proliferation
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Image 4.5 Cell Viability and Apoptotic Activity
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Image 4.6 Western Blot Analysis
Discussion
The results indicate that there is an increase in apoptotic activity
(Caspase 3 assay) and decrease in cell viability (MTT) assay with
regards to Vegf inhibition (Bevacizumab), gal-1 inhibition (OTX
008), and a combination of Vegf + gal 1 inhibition (Bevacizumab +
OTX 008). The sharpest decrease comes in the form of the
combinational treatment, indicating that it might be the most
feasible way to reduce the functionality of the tumor cells. At the
same time Gal-1 expression is influenced by common treatment
methods that are generally given in the clinic for either GB or
recurrent GB. Both co culture assays with Bevacizumab and
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radiation showed a sharp increase in Gal-1 compared with the
control. These increases amounted to approximately 18-24% in
both cases. These results specify Gal-1 expression and the
alteration of Gal-1 expression that takes place in blood cells. A
direct correlation was portrayed by Gal-1 expression and
endothelial cell proliferation in response to treatments. This direct
correlation has the potential to be a mechanism that tumors
incorporate to keep vasculature and promote angiogenesis even in
the presence of treatment. From this data, we decided to go a step
further and investigate the response to a mouse glioblastoma cell
line injected into a C57BL6/J mouse.
Chapter 5
Introduction
The goal of this study was to look deeper at the potential of Gal-1
inhibition with or without conjunction of VEGF inhibition. The invitro studies drug studies were for validation of the concept of Gal-1
as a potential therapeutic target. The next step was to look at the
potential therapeutic or combinations of the potential therapeutic for
the treatment of GB in a relevant mouse model. Mouse models
provide further validation of therapeutic success due to their more
realistic stimulation. For the mouse, you have a similar
microenvironment that holds microglia, astrocytes, and similar
neuronal structure to the human brain. This method of
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experimentation gives a better indication of the effectiveness of the
therapeutic.
Materials and Methods
Schematic 5.1: Experiment Design of Mouse Model

Gl 261 (mouse glioblastoma cell line) were grown to 30%
confluency. Cells were washed three times with PBS and then
centrifuged at 5,000rpm for 5 minutes. Following that cells were
suspended in 5 µl of PBS, and ready for use of injection.
Bevacizumab Recurrent Model
The Bevacizumab recurrent model had a slightly different timepoint
then the previous described schematic and detail of the mouse
Glioblastoma model. The Alzet mini pump was placed in the same
time period shortly after implantation of the Gl 261 tumor cells. AntiVEGF therapy started immediately on the first day. After 14 days
Magnetic Residence Imaging (MRI) was conducted on the mice for
verification of tumor. Only the mice with validation of tumor growth
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were selected for treatment with OTX 008 and the bed of the Alzet
mini pump was replaced with OTX 008. The goal of these studies
was to see the feasibility of Gal-1 inhibition in a relevant
Bevacizumab recurrent model.
Dissection of Brain
Mice were sacrificed following survival analysis. After animal
sacrifice surgical scissors were used to cut through the skin
covering the skull, and then used to cut the skull posterior to
anterior to give a clear image of the brain. The brain was then
gently pulled out of the mice to give a clear path to cut the
connection of the spinal cord to the brain. From this point a scalpel
was used to cut the connection, and brains were labeled
appropriately in tinfoil boats. The tinfoil boats were filled with tissue
freezing medium to protect the genetic profile of the brain and
stored at -80°C for later use.
Cryostat Sectioning
The brains defrosted for 5 minutes before specimens were
mounted on a specimen chuck. The brains were mounted in a
manner shown by schematic 5.2 below. The schematic shows that
mounted occurred posterior to anterior with cerebellum facing up
and being the first part to be sliced. Contact with the tumor began
shortly after finishing slicing cerebellum. Slices were collected on
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permafrost glass slides and stored at -80°C freezer until staining
protocols started.
Antibodies, Microscope, and Software
Table 5.1 Antibodies used for Staining.
Primary Antibody
Santa Cruz CD 133 Rabbit pAb
Sigma Hif-1α rabbit mAb
Abcam Ki-67 rabbit mAb
Abcam Galectin 1 rabbit mAb
Sigma VEGF-A rabbit pAb
Mtl International Survivin rabbit pAb

Secondary Antibody
Abcam Goat pAb to Rabbit Alexflour 488
Abcam Goat pAb to Rabbit Alexflour 489
Abcam Goat pAb to Rabbit Alexflour 490
Abcam Goat pAb to Rabbit Alexflour 491
Thermo Scientific Goat Anti Rabbit Dylight 594
Abcam Goat pAb to Rabbit Alexflour 493

Table 5.1 is meant to identify the types of primary and secondary
antibodies used for the purpose of IF imaging. The device used for
the imaging is the Olympus DP 80 multicolor image camera
attached to a confocal microscope. The set up is inverted with the
tissue slides placed face down for imaging. The software used to
image and quantified the pixel area for the fluorescence excitation
is cellSens by Olympus. Three images were taken on each brain
with 10 tumor slices per brain. The pixel area of the fluorescence
excitation was calculated as along with the standard deviation.
Immunofluorescence Staining
Slides are taken out of the -80° C freeze and allowed to come to
room temperature by incubating for 45 minutes to an hour. Then
slides are immersed in 95% EtOH for 10 min followed by two
washes in PBS (1X) for 2.5 minutes each. The slides are moved to
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a solution of 4% paraformaldehyde dissolved in PBS (1X) where
they are immersed for 15 minutes followed by three washes with
PBS (1X) for 2.5 minutes each. Following the washes with PBS
(1X) the slides are immersed in 0.2% Triton X-100 dissolved in PBS
(1X) for 5 minutes followed by another three washes of PBS (1X)
for 2.5 minutes each. 100µl/slide of 4% serum in PBS(1X) is
applied to each slide for an hour for blocking. The serum is
dependent upon the species of the secondary antibody. In our
experiments the secondary antibody is goat, so the serum is 4%
goat serum in PBS (1X). The 4% goat serum in PBS (1x) is wiped
away from the edges not touching the tissue by a Kimwipe, then
100µl of the primary antibody(1:500 dilution) is applied to each slide
for 2 hours at RT followed by three washes of PBS (1X) at 2.5
minutes each. After the three washes with PBS (1X), 100µl per
slide of secondary antibody (1: 500 dilution) in 4% goat serum in
PBS (1X) is applied to the slides for 1 hour at RT. Application of the
secondary antibody and the following steps must occur in the dark.
Ensuing secondary antibody incubation, the slides are washed
three times with PBS (1X) at 2.5 minutes each. Kim wipes are used
to dry the edges around the tissue in the slides and a plastic
Pasteur pipette is used to incorporate 1-2 droplets of Vectashield+
Dapi onto the slides. Cover slips follow this process and are placed
over the mounted stained tissue. Slides can be kept for 2-3 days for
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optimal imaging at 4°C or -80°C for longer storage and are imaged
using an Olympus microscope.
Results

Image 5.1 Ki-67 Cell Proliferation Analysis: Mouse Samples

Image 5.2 CD 133 Cancer Stem Cell Analysis: Mouse Samples
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Image 5.3 VEGF-A and Gal-1 Expression Analysis: Mouse
Samples

Image 5.4 Survivin Apoptotic Activity Analysis: Mouse Samples
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Image 5.5 Hif-1α Hypoxia Analysis: Mouse Samples
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Table 5.2: Ki-67, Hif-1 α, Survivin, & CD 133 Immunofluorescence
Pixel Area(µm2)

Ki-67

Pixel Area µm squared Standard Error (%)

No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

1410.25
659.2
904.28
402.63
1137.56

0.0017
0.0027
0.0025
0.0116
0.0066

1347.42
910.16
1012.23
342.43
1218.67

0.0050
0.0060
0.0086
0.0073
0.0061

2063.32
254.81
609.27
78.86
128.82

0.0055
0.0327
0.0201
0.0153
0.0059

1085.1925
463.27
527.86
109.87
210.78

0.0021
0.0089
0.0080
0.0219
0.0108

Survivin
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

CD 133
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

Hif-1 α
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008
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Table 5.3 Gal-1, VEGF-A, & Co-localization between VEGF-A and
Gal-1 Immunofluorescence Pixel Area (µm2)
Pixel Area µm squared Standard Error (%)
Gal-1
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

347.81
128.61
278.41
28.27
4.63

0.0189
0.0172
0.0161
0.0258
0.0518

420.26
807.23
694.2
455.53
81.68

0.0177
0.0128
0.0133
0.0143
0.0204

1134.24
81.68
2340.56
62.83
3.47

0.0130
0.0225
0.0072
0.0194
0.0317

VEGF-A
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

VEGF-A & Gal-1 Co-localization
No treatment
OTX008
Bevacizumab
OTX 008+ Bevacizumab
Recurrent Bevacizumab + OTX 008

Discussion
Staining allows for imagery in science which can be novel and help
piece together relationships of various factors between different
treatment methods. The goal of these stains was to visualize
hypoxia, cancer proliferation, cancer stem cell populations, VEGFA, Gal-1, and anti-apoptotic activity across the treatment groups of
no treatment, Gal-1 inhibition through OTX 008, VEGF inhibition
through Bevacizumab, a combination of the two, and a recurrent
VEGF model. Ki-67 showed a vast proliferation in untreated and
recurrent GB. There were similar expressions of Ki-67 in
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Bevacizumab treated and OTX 008 treated. CD 133 and Survivin
had the highest expression in untreated while both single
treatments had less but near equal amounts. The combinational
treatment had the lowest expression of CD 133, Survivin, Ki-67,
and Hif-1 α. This expressional analysis indicates that a dual therapy
is the best option to combat the angiogenesis and hypoxia
characteristics of the tumor microenvironment. VEGF-A expression
was the highest in untreated and Gal-1 but there was still
expression in the other models. VEGF-A has expression in the
other models indicating it is still in the environment. The pixel area
of fluorescence intensity illustrates the same results depicted in the
images.
Chapter 6: Conclusion
The evidence collected points towards Gal-1 expression playing
a role in promoting GB survival and growth. GB in the presence of
standard treatment methods utilizes Gal-1 to maintain angiogenesis
and hypoxia of the tumor microenvironment. Inhibition of Gal-1
leads to a decrease in cell viability (MTT assay) and an increase in
apoptotic activity (Caspase 3). Endothelial cell proliferation and
increase in Gal-1 expression in response to GB cells being treated
with Bevacizumab or OTX 008 indicates Gal-1 expression rescues
endothelial cell proliferation and angiogenesis capacities. Gal-1
keeps expression of Hif-1 complex active even in the presence of
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VEGF inhibition by Bevacizumab. These results show strong direct
correlations between Gal-1 hypoxia, angiogenesis, and inhibition of
apoptotic activity.
These results are promising showing that Gal-1 plays an important
role in maintaining the GB microenvironment and allowing for GB
progression. The next steps to follow these experiments will take a
closer look at the role that complex N-glycans are playing in the
tumor microenvironment. Is it purely Gal-1 expression that drives
recovery of angiogenesis or is it dependent upon the glycome
profile of the microenvironment? A knockout with a specific
antibody to block complex n glycans would enable to see if its an
internal activation of Gal-1 in some sort of positive feedback loop or
N-glycans allowing Gal-1 to bind and keep VEGFR2 pathways
open. Next I would create a humanized mouse model with CD 34+
stem cells to implant human GB tumor samples in the brain. The
focus of this experiment is to conduct survival analysis and look at
populations of macrophages, NK cells, T cells, and dendritic cells.
A clear understanding of the immune effector cell phenotype with or
without Gal-1 inhibition will illustrate Gal-1 role in the immune
microenvironment. These experiments will further identify and
single out mechanisms of Gal-1 vs mechanisms of glycans in the
tumor microenvironment. VEGF-A still had expression across
blockage from Bevacizumab so research to identify if it binds to
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other receptors or still has influence in TME could help answer
questions to why Bevacizumab is not effective in patients and
certain tumor types.
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